Compare Stocks: CRON, DYN, IDYA, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$3.18 -2.5%	$3.02	$2.28 ▼ $3.61	$1.20B	0.94	1.31 million shs	927,991 shs
DYN Dyne Therapeutics	$20.31 -16.4%	$24.82	$11.92 ▼ $27.31	$4.53B	1.08	1.54 million shs	17.15 million shs
IDYA IDEAYA Biosciences	$38.84 -2.6%	$37.70	$23.53 ▼ $42.68	$3.50B	-0.07	675,594 shs	805,943 shs
RYTM Rhythm Pharmaceuticals	$101.80 -0.9%	$109.26	$74.50 ▼ $122.20	$7.04B	1.97	459,115 shs	513,049 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	-2.45%	-5.92%	+2.58%	+16.06%	+28.23%
DYN Dyne Therapeutics	-16.35%	-19.08%	-22.63%	+14.94%	+52.71%
IDYA IDEAYA Biosciences	-2.56%	-2.78%	+4.92%	+40.72%	+66.05%
RYTM Rhythm Pharmaceuticals	-0.91%	-2.81%	-11.96%	+18.77%	+2.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$3.18 -2.5%	$3.02	$2.28 ▼ $3.61	$1.20B	0.94	1.31 million shs	927,991 shs
DYN Dyne Therapeutics	$20.31 -16.4%	$24.82	$11.92 ▼ $27.31	$4.53B	1.08	1.54 million shs	17.15 million shs
IDYA IDEAYA Biosciences	$38.84 -2.6%	$37.70	$23.53 ▼ $42.68	$3.50B	-0.07	675,594 shs	805,943 shs
RYTM Rhythm Pharmaceuticals	$101.80 -0.9%	$109.26	$74.50 ▼ $122.20	$7.04B	1.97	459,115 shs	513,049 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	-2.45%	-5.92%	+2.58%	+16.06%	+28.23%
DYN Dyne Therapeutics	-16.35%	-19.08%	-22.63%	+14.94%	+52.71%
IDYA IDEAYA Biosciences	-2.56%	-2.78%	+4.92%	+40.72%	+66.05%
RYTM Rhythm Pharmaceuticals	-0.91%	-2.81%	-11.96%	+18.77%	+2.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	2.60	Moderate Buy	$2.30	-27.67% Downside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.17	68.23% Upside
IDYA IDEAYA Biosciences	2.80	Moderate Buy	$52.46	35.07% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	38.62% Upside

Current Analyst Ratings Breakdown

Latest CRON, DYN, IDYA, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$37.00
9/1/2026	IDYA IDEAYA Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/1/2026	IDYA IDEAYA Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/1/2026	IDYA IDEAYA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$42.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/26/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00

(Data available from 9/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$146.59M	7.99	$0.01 per share	260.03	$3.00 per share	1.06
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
IDYA IDEAYA Biosciences	$218.71M	15.60	N/A	N/A	$11.67 per share	3.33
RYTM Rhythm Pharmaceuticals	$189.76M	36.76	N/A	N/A	$2.08 per share	48.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	-$9.45M	$0.20	15.90	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/9/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest CRON, DYN, IDYA, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	16.18	15.25
DYN Dyne Therapeutics	0.28	12.02	12.02
IDYA IDEAYA Biosciences	N/A	10.45	10.45
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
DYN Dyne Therapeutics	96.68%
IDYA IDEAYA Biosciences	98.29%
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.80%
DYN Dyne Therapeutics	9.46%
IDYA IDEAYA Biosciences	4.70%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	368.54 million	339.80 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable

CRON, DYN, IDYA, and RYTM Headlines

Recent News About These Companies

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 5, 2026 | marketbeat.com

43,908 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Acquired by Legal & General Group Plc

September 4, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Shares Acquired by Wellington Management Group LLP

September 4, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $57.16 Million Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

September 3, 2026 | marketbeat.com

Braidwell LP Acquires 70,500 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

September 3, 2026 | marketbeat.com

Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth

September 2, 2026 | ad-hoc-news.deA

Rhythm Pharmaceuticals (NASDAQ:RYTM) CFO Sells $6,620,146.04 in Stock

September 2, 2026 | insidertrades.com

Hunter Smith Sells 62,774 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

September 1, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Makes New $6.35 Million Investment in Rhythm Pharmaceuticals, Inc. $RYTM

August 31, 2026 | marketbeat.com

47,400 Shares in Rhythm Pharmaceuticals, Inc. $RYTM Bought by Canada Pension Plan Investment Board

August 31, 2026 | marketbeat.com

Man Group plc Takes $5.64 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 30, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases Shares of 394,044 Rhythm Pharmaceuticals, Inc. $RYTM

August 28, 2026 | marketbeat.com

Jupiter Topco LLC Acquires Shares of 925,490 Rhythm Pharmaceuticals, Inc. $RYTM

August 27, 2026 | marketbeat.com

EFG International AG Invests $3.73 Million in Rhythm Pharmaceuticals, Inc. $RYTM

August 27, 2026 | marketbeat.com

Primecap Management Co. CA Invests $351.84 Million in Rhythm Pharmaceuticals, Inc. $RYTM

August 26, 2026 | marketbeat.com

Connor Clark & Lunn Investment Management Ltd. Acquires New Stake in Rhythm Pharmaceuticals, Inc. $RYTM

August 26, 2026 | marketbeat.com

Algert Global LLC Grows Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Rhythm Pharmaceuticals, Inc. $RYTM

August 26, 2026 | marketbeat.com

Nicholas Investment Partners LP Makes New $15.46 Million Investment in Rhythm Pharmaceuticals, Inc. $RYTM

August 25, 2026 | marketbeat.com

Nan Fung Group Holdings Ltd Purchases New Position in Rhythm Pharmaceuticals, Inc. $RYTM

August 25, 2026 | marketbeat.com

Rhythm Pharmaceuticals Receives Japan Approval for Imcivree

August 24, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CRON, DYN, IDYA, and RYTM Company Descriptions

Cronos Group NASDAQ:CRON

$3.18 -0.08 (-2.45%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$3.19 +0.01 (+0.31%)

As of 09/8/2026 07:30 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Dyne Therapeutics NASDAQ:DYN

$20.31 -3.97 (-16.35%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$19.58 -0.72 (-3.57%)

As of 09/8/2026 07:58 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

IDEAYA Biosciences NASDAQ:IDYA

$38.84 -1.02 (-2.56%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$38.83 -0.02 (-0.04%)

As of 09/8/2026 07:30 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$101.80 -0.94 (-0.91%)

Closing price 09/8/2026 04:00 PM Eastern

Extended Trading

$101.81 +0.01 (+0.01%)

As of 09/8/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRON, DYN, IDYA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRON, DYN, IDYA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRON, DYN, IDYA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRON, DYN, IDYA, and RYTM Company Descriptions

Cronos Group NASDAQ:CRON

Dyne Therapeutics NASDAQ:DYN

IDEAYA Biosciences NASDAQ:IDYA

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRON, DYN, IDYA, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRON, DYN, IDYA, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRON, DYN, IDYA, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CRON, DYN, IDYA, and RYTM Company Descriptions

Cronos Group NASDAQ:CRON

Dyne Therapeutics NASDAQ:DYN

IDEAYA Biosciences NASDAQ:IDYA

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools